| Chairman |
|
Tang Li |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman: Tang Li
Vice Chairman, Chief Executive Officer & General Manager: Qiu Rongguo
Executive Director: Zhang Cheng, Guan Jin
Non-executive Director: Tang Jin, Zhu Pai
Independent Non-executive Director: Meng Songdong, Qi Jingyao, Ran Dong.
|
| Principle Business |
|
The Group is principally engaged in biopharmaceutical business in the PRC, focusing on developing innovative drugs in oncology. |
| Major Shareholders |
| Tang Li & ASSO | 37,577,357 | NON-H SHS | 10.31% | 25.41% | 2024/10/31 | | SDIC VC Fund (Shanghai) of Technology Transfer and Commercialization | 29,426,685 | NON-H SHS | 8.07% | 19.90% | 2024/10/31 | | Shanghai Xin Sheng De Yuan Enterprise Management Centre (Limited Partnership) | 28,000,000 | H Sh | 7.68% | 12.92% | 2024/10/31 | | Tang Li & ASSO | 25,051,572 | H Sh | 6.87% | 11.56% | 2024/10/31 | | Efung Investment Management Limited Partnership Enterprise | 21,827,261 | H Sh | 5.99% | 10.07% | 2024/10/31 | | Baygen QT Inc. | 20,252,943 | H Sh | 5.56% | 9.35% | 2024/10/31 | | Baygen QT Inc. | 20,252,942 | NON-H SHS | 5.56% | 13.70% | 2024/10/31 | | Shanghai Haidai Botai Enterprise Management Centre (Limited Partnership) | 12,237,963 | NON-H SHS | 3.36% | 8.28% | 2024/10/31 | | Shanghai Haidai Botai Enterprise Management Centre (Limited Partnership) | 12,237,963 | H Sh | 3.36% | 5.65% | 2024/10/31 | | Shanghai Xin Sheng De Yuan Enterprise Management Centre (Limited Partnership) | 6,798,296 | NON-H SHS | 1.86% | 4.60% | 2024/10/31 |
|
|
|
|
|